Business
IceCure Medical to Attend the 2025 Maxim Growth Summit
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that members of the Company's management, including Eyal Shamir, Chief Executive Officer, will be participating in Maxim's Growth Summit held in New York City on October 22nd and 23rd, 2025. The Company management will be meeting with institutional investors in a one-on
About this update from Icecure Medical Ltd.
[{"type":"text","content":"IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer","length":203,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, Oct. 9, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that members of the Company's management, including Eyal Shamir, Chief Executive Officer, will be participating in Maxim's Growth Summit held in New York City on October 22nd and 23rd, 2025. The Company management will be meeting with institutional investors in a one-on-one format and will provide an overview of the Company, including its latest regulatory and commercial milestones in the U.S. and global markets.","length":731,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":"IceCure's ProSense® cryoablation system recently received the U.S. Food and Drug Administration's ("FDA") marketing authorization for the local treatment of early-stage, low risk breast cancer in patients ≥70 years of age and women not suitable for surgery for breast cancer treatment. ProSense® offers the first new innovation in the treatment of women with low-risk early-stage breast cancer in decades and has the potential to set a new standard of care for the defined indication.","length":507,"tagName":"p"},{"type":"text","content":"Investors should reach out to their Maxim sales representatives, or Michael Polyviou at [email protected] to schedule meetings with IceCure Medical's management team.","length":180,"tagName":"p"},{"type":"text","content":...